Holen Sie sich die Stockscreener-App
40.63
0.54%
0.22
Handel nachbörslich:
40.65
0.02
+0.05%
Schlusskurs vom Vortag:
$40.41
Offen:
$40.43
24-Stunden-Volumen:
6.05M
Relative Volume:
1.29
Marktkapitalisierung:
$5.19B
Einnahmen:
$1.00B
Nettoeinkommen (Verlust:
$22.39M
KGV:
328.99
EPS:
0.1235
Netto-Cashflow:
$45.01M
1W Leistung:
+137.74%
1M Leistung:
+102.44%
6M Leistung:
+66.79%
1J Leistung:
+103.46%
1-Tages-Spanne:
$40.41
$40.69
1-Wochen-Bereich:
$40.22
$40.69
52-Wochen-Spanne:
$16.10
$40.69
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Firmenname
Apellis Pharmaceuticals Inc
Sektor
Branche
Telefon
617-977-5700
Adresse
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
40.63 | 5.17B | 1.00B | 22.39M | 45.01M | 0.1235 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-13 | Eingeleitet | Roth Capital | Buy |
| 2026-01-28 | Eingeleitet | Barclays | Equal Weight |
| 2026-01-21 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-11-06 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-10-15 | Eingeleitet | Wells Fargo | Overweight |
| 2025-09-26 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-09 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-05-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Herabstufung | Goldman | Buy → Neutral |
| 2024-11-21 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-16 | Eingeleitet | William Blair | Outperform |
| 2024-05-31 | Eingeleitet | Piper Sandler | Neutral |
| 2024-02-05 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-02 | Eingeleitet | Mizuho | Neutral |
| 2023-10-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Bestätigt | Citigroup | Buy |
| 2023-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-17 | Fortgesetzt | Stifel | Buy |
| 2022-04-14 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-29 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-09-10 | Bestätigt | Credit Suisse | Neutral |
| 2021-09-10 | Bestätigt | Needham | Buy |
| 2021-09-10 | Bestätigt | Oppenheimer | Outperform |
| 2021-09-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-08-19 | Eingeleitet | Jefferies | Buy |
| 2021-08-19 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2020-11-19 | Eingeleitet | Needham | Buy |
| 2020-09-01 | Eingeleitet | Stifel | Buy |
| 2020-07-20 | Eingeleitet | ROTH Capital | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-04-01 | Eingeleitet | Raymond James | Strong Buy |
| 2020-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-11 | Hochstufung | Wedbush | Underperform → Neutral |
| 2020-01-07 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-12-19 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-22 | Eingeleitet | Wedbush | Underperform |
| 2019-11-05 | Eingeleitet | Credit Suisse | Neutral |
| 2019-08-01 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten
Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 12-Month HighWhat's Next? - MarketBeat
Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here's What Shareholders Get - Benzinga
Apellis Pharmaceuticals, Inc. (APLS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Biogen’s Apellis Deal Reshapes Growth Outlook And Valuation Story - Yahoo Finance
APLS PE Ratio & Valuation, Is APLS Overvalued - Intellectia AI
Biogen Bets Big on Kidney Drugs with USD 5.6 Billion Apellis Pharmaceuticals Deal - Medical Dialogues
Apellis Pharmaceuticals (APLS) hits 2-year high on 140% upside from Biogen merger - MSN
Biogen (NASDAQ: BIIB) plans tender offer to acquire Apellis (APLS); materials pending - Stock Titan
Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptcy - Benzinga
Biogen to acquire Apellis in $5.6 billion deal - Ophthalmology Times
Apellis Pharmaceuticals (NASDAQ:APLS) Downgraded by Roth Mkm to "Hold" - MarketBeat
Comparing Apellis Pharmaceuticals With Industry Competitors In Biotechnology Industry - Sahm
Apellis surges on $5.6B buyout deal with Biogen - MSN
APLS Stock Soars 140% Today – Here’s Everything To Know About Apellis' Massive $5.6B Deal With Biogen - Stocktwits
Biogen’s $5.6 Billion Apellis Buy Drives Top Trading Volume Amid Share Price Slide - Bitget
Why Biogen Is Paying $5.6B to Buy Apellis Pharma - MedCity News
Apellis Pharmaceuticals (APLS): Mizuho Raises Price Target Amids - gurufocus.com
Mizuho Increases Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $41.00 - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Downgraded to "Hold" Rating by Jefferies Financial Group - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Downgraded to "Hold" Rating by William Blair - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Downgraded to Hold Rating by Cantor Fitzgerald - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Lowered to Hold Rating by Citigroup - MarketBeat
H.C. Wainwright raises Biogen stock price target on Apellis deal - Investing.com
Apellis Pharmaceuticals (NASDAQ:APLS) Emerges as a Prime Affordable Growth (GARP) Candidate - ChartMill
Biogen to Acquire Apellis Pharmaceuticals in $5.6 Billion Deal - eHealth Magazine
Roth/MKM downgrades Apellis stock rating on Biogen acquisition - Investing.com
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) - Sahm
Apellis Pharmaceuticals (APLS) Moves 135.4% Higher: Will This Strength Last? - qz.com
Biogen Acquires Apellis for $5.6B, Shares Dip | Strategic Immunology MoveNews and Statistics - IndexBox
APLS: Barclays Raises Price Target for Apellis Pharmaceuticals | - gurufocus.com
APLS: JP Morgan Downgrades Apellis Pharmaceuticals, Raises Price Target | APLS Stock News - gurufocus.com
Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets - BioPharma Dive
How The Apellis Pharmaceuticals (APLS) Investment Story Is Shifting With New Deals And Analyst Revisions - Yahoo Finance
Apellis Pharmaceuticals, Inc. (APLS) Stock Forecasts - Yahoo Finance
JPMorgan Chase & Co. Reaffirms Neutral Rating for Apellis Pharmaceuticals (NASDAQ:APLS) - MarketBeat
Watch Biogen Buys Apellis for $5.6B to Expand Kidney Drugs - Bloomberg.com
American Biogen bought assets of Apellis Pharmaceuticals for $5.6 billion - AKM.RU
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Expected to Rise, Barclays Analyst Says - MarketBeat
Biogen to acquire Apellis Pharmaceuticals for $5.6 billion By Investing.com - Investing.com Canada
Biogen’s $5.6bn Apellis Deal Delivers Windfall for Worldwide Healthcare Trust - TipRanks
Apellis Pharmaceuticals (NASDAQ:APLS) Sees Large Volume IncreaseWhat's Next? - MarketBeat
APLS Downgraded by Raymond James to Market Perform | APLS Stock News - GuruFocus
A Look At Apellis Pharmaceuticals (APLS) Valuation After Its Sharp Recent Share Price Surge - simplywall.st
Worldwide Healthcare Trust PLCBiogen, Inc. to acquire WWH portfolio company, Apellis Pharmaceuticals, Inc. - bolsamania.com
Apellis Pharmaceuticals (NASDAQ:APLS) Receives "Market Perform" Rating from Raymond James Financial - MarketBeat
Mizuho raises Apellis stock price target to $41 on Biogen deal - investing.com
Biogen Enters $5.6 Billion Agreement to Acquire Apellis Pharmaceuticals - pharmexec.com
APLS Downgraded by Citigroup: Target Price Lowered to $41.00 | A - GuruFocus
This PPG Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio - Yahoo Finance
Apellis Pharmaceuticals (NASDAQ:APLS) Given Neutral Rating at Citigroup - MarketBeat
Finanzdaten der Apellis Pharmaceuticals Inc-Aktie (APLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):